Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens

Experimental Hematology

Volumn 36, Issue 11, 2008, Pages 1480-1486.e2

  Moliterno, Alison R ^a   Williams, Donna M ^a   Rogers, Ophelia ^a   Isaacs, Mary Ann ^a   Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; GENOMIC DNA; HYDROXYUREA; INTERFERON; JANUS KINASE 2; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD34 SELECTION; CELL CLONING; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DOMINANT GENE; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; NEUTROPHIL; PHENOTYPE; PHENOTYPIC VARIATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLEEN SIZE; SPLENOMEGALY; STEM CELL; THROMBOCYTOSIS; ADOLESCENT; ALLELE; GENETICS; HEMATOPOIETIC STEM CELL; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; PHENOTYPE; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 53749103194     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.05.006     Document Type: Article

References (44)

1. Adamson J.W., Fialkow P.J., Murphy S., Prchal J.F., and Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 295 (1976) 913-916
2. Najfeld V., Montella L., Scalise A., and Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119 (2002) 558-566
3. Prchal J.F., and Axelrad A.A. Letter: bone-marrow responses in polycythemia vera. N Engl J Med 290 (1974) 1382
4. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 9464 (2005) 1054-1061
5. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
6. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 7037 (2005) 1144-1148
7. Adamson J.W., Singer J.W., Catalano P., et al. Polycythemia vera. Further in vitro studies of hematopoietic regulation. J Clin Invest 66 (1980) 1363-1368
8. Dupont S., Masse A., James C., et al. The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110 (2007) 1013-1021
9. Yamamoto G., Nannya Y., Kato M., et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of Affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81 (2007) 114-126
10. Scott L.M., Scott M.A., Campbell P.J., and Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108 (2006) 2435-2437
11. Berk P.D., Goldberg J.D., Donovan P.B., Fruchtman S.M., Berlin N.I., and Wasserman L.R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23 (1986) 132-143
12. Mesa R.A., Verstovsek S., Cervantes F., et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 31 (2007) 737-740
13. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 (1999) 2954-2970
14. Moliterno A.R., Williams D.M., Rogers O., and Spivak J.L. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108 (2006) 3913-3915
15. Barosi G., Viarengo G., Pecci A., et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98 (2001) 3249-3255
16. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 (2007) 840-846
17. Passamonti F., Rumi E., Pietra D., et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 107 (2006) 3676-3682
18. Larsen T.S., Pallisgaard N., Moller M.B., and Hasselbalch H.C. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 79 (2007) 508-515
19. Prchal J.F., Adamson J.W., Murphy S., Steinmann L., and Fialkow P.J. Polycythemia vera. The in vitro response of normal and abnormal stem cell lines to erythropoietin. J Clin Invest 61 (1978) 1044-1047
20. Golde D.W., Hocking W.G., Koeffler H.P., and Adamson J.W. Polycythemia: mechanisms and management. Ann Intern Med 95 (1981) 71-87
21. Ishii T., Bruno E., Hoffman R., and Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108 (2006) 3128-3134
22. Lacombe C., Casadevall N., and Varet B. Polycythaemia vera: in vitro studies of circulating erythroid progenitors. Br J Haematol 44 (1980) 189-199
23. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
24. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
25. Macdonald D., and Cross N.C. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. Pathobiology 74 (2007) 81-88
26. El Kassar N., Hetet G., Li Y., Briere J., and Grandchamp B. Clonal analysis of haemopoietic cells in essential thrombocythaemia. Br J Haematol 90 (1995) 131-137
27. Ferraris A.M., Mangerini R., Racchi O., et al. Heterogeneity of clonal development in chronic myeloproliferative disorders. Am J Hematol 60 (1999) 158-160
28. Gilliland D.G., Blanchard K.L., Levy J., Perrin S., and Bunn H.F. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A 88 (1991) 6848-6852
29. El-Kassar N., Hetet G., Briere J., and Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 89 (1997) 128-134
30. Kiladjian J.J., Elkassar N., Cassinat B., et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 20 (2006) 1181-1183
31. Pemmaraju N., Moliterno A.R., Williams D.M., Rogers O., and Spivak J.L. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21 (2007) 2210-2212
32. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
33. Parganas E., Wang D., Stravopodis D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 (1998) 385-395
34. Eaves C.J., and Eaves A.C. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 52 (1978) 1196-1210
35. Falanga A., Marchetti M., Vignoli A., et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35 (2007) 702-711
36. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 9501 (2005) 1945-1953
37. Najean Y., and Rain J.D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90 (1997) 3370-3377
38. Tefferi A., Gangat N., and Wolanskyj A.P. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?. Blood 108 (2006) 2493-2494
39. Berk P.D., Goldberg J.D., Silverstein M.N., et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304 (1981) 441-447
40. Tubiana M., Flamant R., Attie E., and Hayat M. A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients). Blood 32 (1968) 536-548
41. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 123 (1995) 656-664
42. Segal J.B., and Moliterno A.R. Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol 16 (2006) 123-130
43. Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., et al. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A 101 (2004) 11444-11447
44. Turhan A.G., Humphries R.K., Cashman J.D., Cuthbert D.A., Eaves C.J., and Eaves A.C. Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder. J Clin Invest 81 (1988) 1999-2003